Biotherapeutics News and Research

RSS

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Gyros Protein Technologies AB today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows.

From Gyros Protein Technologies AB 27 Jan 2021

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.

3 Dec 2020

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.

Horizon Discovery today announced that it has granted commercial licenses for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals.

From Revvity 2 Dec 2020

Researchers successfully edit SIV virus from genomes of non-human primates

Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV - a virus closely related to HIV, the cause of AIDS - from the genomes of non-human primates.

1 Dec 2020

Unique training program is bolstering Canada’s capacity to manufacture novel biotherapeutics

As COVID-19 highlights the urgent need to increase vaccine manufacturing around the world, a unique training program is bolstering Canada's capacity to manufacture vaccines, as well as viral immunotherapies for cancer and other emerging biotherapeutics.

23 Nov 2020

Lonza provides expansive selection of high-resolution HLA-typed primary cells to boost drug development

Lonza has announced that it now provides an expansive selection of high-resolution Human Leukocyte Antigen (HLA)-typed primary cells spanning all major cell and tissue types.

From Lonza 20 Nov 2020

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced the appointment of Stewart Kay as Chief Business Officer.

28 Oct 2020

New DNA-cutting tool could advance gene editing for novel treatments

Gene editing for the development of new treatments, and for studying disease as well as normal function in humans and other organisms, may advance more quickly with a new tool for cutting larger pieces of DNA out of a cell's genome, according to a new study by UC San Francisco scientists.

21 Oct 2020

Novel microfluidic approach to fight cancer could greatly benefit patients

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

20 Oct 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing.

From Gyros Protein Technologies AB 3 Sep 2020

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.

From Avacta Life Sciences Ltd. 3 Sep 2020

New diagnostic tool can predict cancer patients' response to immunotherapy

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

27 Aug 2020

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT serum half-life extension system.

From Avacta Life Sciences Ltd. 21 Aug 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020

Biotherapeutics News and Research

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

New antiviral drug completely suppresses SARS-CoV-2 transmission within 24 hours

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.

Researchers successfully edit SIV virus from genomes of non-human primates

Unique training program is bolstering Canada’s capacity to manufacture novel biotherapeutics

Lonza provides expansive selection of high-resolution HLA-typed primary cells to boost drug development

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

New DNA-cutting tool could advance gene editing for novel treatments

Novel microfluidic approach to fight cancer could greatly benefit patients

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

New diagnostic tool can predict cancer patients' response to immunotherapy

Avacta expands multi-target collaboration with LG Chem Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring